Filing search / Inhibrx Biosciences, Inc. / "Safety"

8-K

INBX Inhibrx Biosciences, Inc.

30 May 24

Termination of a Material Definitive Agreement

4:13pm

the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of INBRX-101 Compared to Plasma Derived Alpha-1 Proteinase Inhibitor (A1PI) Augmentation Therapy

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

9 May 24

Inhibrx Reports First Quarter 2024 Financial Results

4:08pm

and beliefs regarding the strength of Inhibrx’s pipeline and the observed safety and efficacy to date of its therapeutic candidates; whether a trial

DEFM14A

INBX Inhibrx Biosciences, Inc.

26 Apr 24

Proxy related to merger

4:06pm

-Control, Parallel Group Study to Assess the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of INBRX-101 Compared to Plasma Derived Alpha-1 … the Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of INBRX-101 Compared to Plasma Derived Alpha-1 Proteinase Inhibitor (A1PI

8-K

EX-99.1

INBX Inhibrx Biosciences, Inc.

28 Feb 24

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

9:12am

’ judgments and beliefs regarding the strength of Inhibrx’s pipeline and the observed safety and efficacy to date of its therapeutic candidates; whether

DEFA14A

ijnsgi pqmayowe3x7do

6 Feb 24

Additional proxy soliciting materials

4:30pm

DEFA14A

zquw7

23 Jan 24

Additional proxy soliciting materials

6:38am

8-K

p30ft 8lx4kw

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.1

uhusabhmcpf

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-2.2

trp2r2bs rtp

23 Jan 24

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

6:35am

8-K

EX-99.1

jqr1m2bly2bv84 91

9 Nov 23

Inhibrx Reports Third Quarter 2023 Financial Results

4:03pm

8-K

EX-99.1

iwd0zj

2 Nov 23

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

9:16am

8-K

7p20k5lvrr0aw4x

2 Nov 23

Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

9:16am

8-K

EX-99.1

5f6gjea5 okb

19 Sep 23

Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada

4:03pm

8-K

EX-99.1

rgewgc xr4

29 Aug 23

Inhibrx Announces $200 Million Private Placement Financing

9:03am

8-K

EX-99.2

wzg0 febqo03a

7 Aug 23

Inhibrx Reports Second Quarter 2023 Financial Results

4:05pm

8-K

EX-99.1

kypsh

7 Aug 23

Inhibrx Reports Second Quarter 2023 Financial Results

4:05pm